Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Increased Drp1 promotes autophagy and ESCC progression by mtDNA stress mediated cGAS-STING pathway

Fig. 2

Drp1 inhibitor or knockdown exhibits an anticancer effect on ESCC in vitro and in vivo. (A and B) Cell proliferation was evaluated by EdU incorporation assay in ESCC cells with Drp1 knockdown or treatment with 50 μM Mdivi-1 for 12 h as indicated. Scale bar: 200 μm. (C and D) Colony-forming potential were detected in ESCC cells with Drp1 knockdown or treatment with 50 μM Mdivi-1 for 12 h as indicated. Scale bar: 10 mm. (E and F) Cell viability of ESCC cells with Drp1 knockdown or treatment with 50 μM Mdivi-1 for 12 h as indicated were evaluated using the MTS cell proliferation assay. (G, H and I, J) Tumor growth curves of subcutaneous xenograft tumor model developed from ESCC cells with Drp1 deficiency (n = 6) or treatment with Mdivi-1 (n = 6). Tumor size including tumor length (L) and width (W) was measured using vernier calipers every week from second week after transplantation. The tumor volumes were calculated according to the formula (L × W2)/2 and presented as mean ± SEM. Tumors from sacrificed mice were dissected fifth week after transplantation and were also shown in lower panel. (K and L) Representative immunohistochemical (IHC) staining images of Ki67 in xenograft tumors developed from KYSE-70 cells with Drp1 deficiency or treatment with Mdivi-1. Scale bar: 100 μm. The data shown are the mean ± SEM from three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. shDrp1, shRNA expression vector against Drp1; shCtrl, control shRNA

Back to article page